Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
Eunice S WangAaron D GoldbergMartin TallmanRoland Bruno WalterChatchada KaranesKaramjeet SandhuCarlos Enrique VigilRobert H CollinsVinay JainRichard M StonePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
-mutant AML results in high rate of deep responses and long-term survival with acceptable toxicity. A randomized trial of crenolanib versus midostaurin plus chemotherapy in younger patients is ongoing.